# Jianming Xu

Source: https://onco.cc/people/xu-jianming/  
OnCo record `xu-jianming` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Jianming Xu led the Chinese stomach cancer trials of sintilimab, the ADC disitamab vedotin and other domestic drugs, in the country with the most stomach cancer patients.

## Summary

Jianming Xu is Professor of Gastrointestinal Oncology at the Fifth Medical Center of the Chinese PLA General Hospital in Beijing. He is best known as principal investigator of ORIENT-16, the randomised trial of sintilimab plus chemotherapy in first-line unresectable gastric and gastro-oesophageal junction cancer reported in JAMA, and of the pivotal gastric cancer study of the HER2 antibody-drug conjugate disitamab vedotin. He has led many Chinese phase 3 trials in gastric, colorectal and oesophageal cancer and is a leading figure in the CSCO gastric cancer guidelines. His trials have brought domestic drugs to the country with the most stomach cancer patients.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Also known as: Xu Jian-Ming; 徐建明
- Tags: china
- Role: Professor of Gastrointestinal Oncology; Fifth Medical Center, Chinese PLA General Hospital, Beijing
- Specialisms: Gastric cancer; Gastrointestinal oncology; Clinical trials; HER2 ADCs

## Sources

- PubMed author search: https://pubmed.ncbi.nlm.nih.gov/?term=Xu%20J%5BAuthor%5D%20gastric%20cancer%20307%20Hospital%20PLA

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- drugs: [Disitamab vedotin](https://onco.cc/drugs/disitamab-vedotin/), [Sintilimab](https://onco.cc/drugs/sintilimab/)
- institutions: [Chinese PLA General Hospital](https://onco.cc/institutions/pla-general-hospital/)
- trials: [ORIENT-16](https://onco.cc/trials/orient-16/)

---
JSON: https://onco.cc/api/v1/entities/xu-jianming.json